PMID- 35195958
OWN - NLM
STAT- MEDLINE
DCOM- 20220421
LR  - 20220519
IS  - 2192-2659 (Electronic)
IS  - 2192-2640 (Linking)
VI  - 11
IP  - 8
DP  - 2022 Apr
TI  - Tumor-Tropic Adipose-Derived Mesenchymal Stromal Cell Mediated Bi(2) Se(3) 
      Nano-Radiosensitizers Delivery for Targeted Radiotherapy of Non-Small Cell Lung 
      Cancer.
PG  - e2200143
LID - 10.1002/adhm.202200143 [doi]
AB  - With the successful marriage between nanotechnology and oncology, various high-Z 
      element containing nanoparticles (NPs) are approved as radiosensitizers to 
      overcome radiation resistance for enhanced radiotherapy (RT). Unfortunately, 
      NPs themselves lack specificity to tumors. Due to the inherent tropism nature of 
      malignant cells, mesenchymal stem cells (MSCs) emerge as cell-mediated delivery 
      vehicles for functional NPs to improve their therapeutic index. Herein, 
      radiosensitive bismuth selenide (Bi(2) Se(3) ) NPs-laden adipose-derived 
      mesenchymal stromal cells (AD-MSCs/Bi(2) Se(3) ) are engineered for targeted RT 
      of non-small cell lung cancer (NSCLC). The results reveal that the optimized 
      intracellular loading strategy hardly affects cell viability, specific surface 
      markers, or migration capability of AD-MSCs, and Bi(2) Se(3)  NPs can be 
      efficiently transported from AD-MSCs to tumor cells. In vivo biodistribution 
      test shows that the Bi(2) Se(3) NPs accumulation in tumor is increased 20 times 
      via AD-MSCs-mediated delivery. Therefore, AD-MSCs/Bi(2) Se(3) 
      administration synchronized with X-ray irradiation controls the tumor progress 
      well in orthotopic A549 tumor bearing mice. Considering that MSCs migrate better 
      to irradiated tumor cells in comparison to nonirradiated ones and MSCs 
      preferentially accumulate within lung tissues after systemic administration into 
      accounts, the tumor-tropic MSCs/NPs system is feasible and promising for targeted 
      RT treatment of NSCLC.
CI  - (c) 2022 Wiley-VCH GmbH.
FAU - Xiao, Jingfang
AU  - Xiao J
AD  - Institute of Pathology and Southwest Cancer Center, The First Affiliated 
      Hospital, Third Military Medical University (Army Medical University), and Key 
      Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, 
      40038, P. R. China.
FAU - Zeng, Lijuan
AU  - Zeng L
AUID- ORCID: 0000-0002-8836-0793
AD  - Institute of Pathology and Southwest Cancer Center, The First Affiliated 
      Hospital, Third Military Medical University (Army Medical University), and Key 
      Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, 
      40038, P. R. China.
FAU - Ding, Shuaishuai
AU  - Ding S
AUID- ORCID: 0000-0002-7151-0038
AD  - Institute of Pathology and Southwest Cancer Center, The First Affiliated 
      Hospital, Third Military Medical University (Army Medical University), and Key 
      Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, 
      40038, P. R. China.
FAU - Chen, Yemiao
AU  - Chen Y
AUID- ORCID: 0000-0001-5397-1407
AD  - Institute of Pathology and Southwest Cancer Center, The First Affiliated 
      Hospital, Third Military Medical University (Army Medical University), and Key 
      Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, 
      40038, P. R. China.
AD  - Biobank of The First Affiliated Hospital, Third Military Medical University (Army 
      Medical University), Chongqing, 40038, P. R. China.
AD  - Clinical Research Center, Chongqing Public Health Medical Center, Chongqing, 
      400036, P. R. China.
FAU - Zhang, Xiao
AU  - Zhang X
AUID- ORCID: 0000-0003-3703-7854
AD  - International Joint Research Center for Precision Biotherapy, and Department of 
      Stem Cell and Regenerative Medicine, The First Affiliated Hospital, Third 
      Military Medical University (Army Medical University), Chongqing, 400038, P. R. 
      China.
FAU - Bian, Xiu-Wu
AU  - Bian XW
AD  - Institute of Pathology and Southwest Cancer Center, The First Affiliated 
      Hospital, Third Military Medical University (Army Medical University), and Key 
      Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, 
      40038, P. R. China.
FAU - Tian, Gan
AU  - Tian G
AUID- ORCID: 0000-0001-5754-3418
AD  - Institute of Pathology and Southwest Cancer Center, The First Affiliated 
      Hospital, Third Military Medical University (Army Medical University), and Key 
      Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, 
      40038, P. R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220304
PL  - Germany
TA  - Adv Healthc Mater
JT  - Advanced healthcare materials
JID - 101581613
RN  - 0 (Radiation-Sensitizing Agents)
SB  - IM
MH  - Animals
MH  - *Carcinoma, Non-Small-Cell Lung/metabolism/radiotherapy
MH  - Cell Line, Tumor
MH  - *Lung Neoplasms/metabolism/radiotherapy
MH  - *Mesenchymal Stem Cell Transplantation/methods
MH  - *Mesenchymal Stem Cells
MH  - Mice
MH  - *Radiation-Sensitizing Agents
MH  - Tissue Distribution
OTO - NOTNLM
OT  - MSC-mediated delivery
OT  - nano-radiosensitizers
OT  - non-small cell lung cancer
OT  - radiotherapy
OT  - targeting
EDAT- 2022/02/24 06:00
MHDA- 2022/04/22 06:00
CRDT- 2022/02/23 12:30
PHST- 2022/02/15 00:00 [revised]
PHST- 2022/01/18 00:00 [received]
PHST- 2022/02/24 06:00 [pubmed]
PHST- 2022/04/22 06:00 [medline]
PHST- 2022/02/23 12:30 [entrez]
AID - 10.1002/adhm.202200143 [doi]
PST - ppublish
SO  - Adv Healthc Mater. 2022 Apr;11(8):e2200143. doi: 10.1002/adhm.202200143. Epub 
      2022 Mar 4.